NEUROCRINE BIOSCIENCES INC 8-K

What Happened

• Neurocrine Biosciences, Inc. announced its financial results for the quarter ended March 31, 2026, via a press release dated May 5, 2026. The press release is attached to the Form 8-K as Exhibit 99.1. The Form 8-K was signed by Matthew C. Abernethy, Chief Financial Officer.

Key Details

• Date of announcement: May 5, 2026.
• Period covered: Quarter ended March 31, 2026 (Q1 2026).
• Disclosure format: Press release furnished as Exhibit 99.1 to Form 8-K (information is furnished, not “filed,” and thus not subject to Section 18 liability per General Instruction B.2).
• Administrative exhibits included: Exhibit 99.1 (press release) and an interactive data file (104).

Why It Matters

• This Form 8-K tells investors that Neurocrine has released its quarterly earnings information; the attached press release will contain the actual earnings, revenue, and any commentary on business trends or guidance.
• Because the release is furnished (not filed), the company limits certain legal liabilities and does not automatically incorporate the release into other SEC filings. Investors should review Exhibit 99.1 for the specific financial figures and management commentary to assess impacts on revenue, profitability, and near-term outlook.